Format

Send to

Choose Destination
See comment in PubMed Commons below
Mult Scler. 2013 Jul;19(8):1106-12. doi: 10.1177/1352458512471878. Epub 2013 Feb 11.

Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.

Author information

1
Multiple Sclerosis Study Center, Hospital of Gallarate, Italy. angelo.ghezzi@aogallarate.it

Abstract

BACKGROUND:

Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients.

OBJECTIVE:

The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MS patients.

METHODS:

Patients with definite ped-MS were treated with NA if in the previous year they had experienced at least two relapses or a severe relapse with incomplete recovery while on immunomodulating treatment, or at least two relapses and new magnetic resonance imaging (MRI) lesions regardless of any prior treatment.

RESULTS:

The study included 55 patients (mean age: 14.4 years, mean number of relapses: 4.4, pre-treatment mean disease duration: 25.5 months). They received a median number of 26 infusions. Three relapses occurred during the follow-up, one female patient continued to deteriorate in cognitive functioning. Mean Expanded Disability Status Scale (EDSS) scores decreased from 2.7 to 1.9 at the last visit (p<0.001). During the follow-up the majority of patients remained free from MRI activity. Transient and mild clinical adverse events occurred in 20 patients. Mild hematological abnormalities occurred in seven patients. Anti-JCV antibodies were detected in 20/51 tested patients.

CONCLUSIONS:

NA was well tolerated in all patients. A strong suppression of disease activity was observed in the majority of patients during the follow-up.

KEYWORDS:

Multiple sclerosis; adolescence; childhood; natalizumab

PMID:
23401129
DOI:
10.1177/1352458512471878
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center